Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers

Endocrine-Related Cancer

Volumn 23, Issue 10, 2016, Pages T69-T84

  Milne, Roger L ^a,b   Antoniou, Antonis C ^c  

^a CANCER EPIDEMIOLOGY CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

BRCA1; BRCA2; Breast cancer; Common genetic variants; Genotype phenotype; Lifestyle hormonal risk factors; Modifier; Ovarian cancer; Risk prediction

Indexed keywords

HORMONE; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

BREAST CANCER; BREAST DENSITY; CANCER RISK; CLINICAL PRACTICE; ENVIRONMENTAL FACTOR; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; HEREDITY; HUMAN; LIFESTYLE; OVARY CANCER; REVIEW; TUMOR SUPPRESSOR GENE; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; MODIFIER GENE; MUTATION; OVARY TUMOR; RISK FACTOR;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENES, MODIFIER; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MUTATION; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 84993949387     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-16-0277     Document Type: Review

References (147)

1. Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, Platte R, Morrison J, Maranian M, Pooley KA, Luben R, et al. 2009 Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics 41 585-590. (doi:10.1038/ng.354)
2. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, et al. 2012 BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology 30 2654-2663. (doi:10.1200/JCO.2011.39.8545)
3. Andrieu N, Goldgar DE, Easton DF, Rookus MA, Brohet R, Antoniou AC, Peack S, Evans DG, Eccles D, Douglas F, et al. 2006 Pregnancies, breastfeeding and breast cancer risk in the Internatioinal BRCA1/2 carrier Cohort Study (IBCCS). Journal of National Cancer Institute 98 535-544. (doi:10.1093/jnci/djj132)
4. Anglian Breast Cancer Study Group 2000 Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. British Journal of Cancer 83 1301-1308. (doi:10.1054/bjoc.2000.1407)
5. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al. 2003 Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. American Journal of Human Genetics 72 1117-1130. (doi:10.1086/375033)
6. Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA & Easton DF 2005a A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genetic Epidemiology 29 1-11. (doi:10.1002/gepi.20074)
7. Antoniou AC, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Olsson H, Johannsson O, Borg A, Pasini B, et al. 2005b Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: A combined analysis of 22 population based studies. Journal of Medical Genetics 42 602-603. (doi:10.1136/jmg.2004.024133)
8. Antoniou AC, Shenton A, Maher ER, Watson E, Woodward E, Lalloo F, Easton DF & Evans DG 2006 Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research 8 R72. (doi:10.1186/bcr1630)
9. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, et al. 2008a The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. British Journal of Cancer 98 1457-1466. (doi:10.1038/sj.bjc.6604305)
10. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, et al. 2008b Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. American Journal of Human Genetics 82 937-948. (doi:10.1016/j.ajhg.2008.02.008)
11. Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, Cook M, Evans DG, Eeles R, Nogues C, et al. 2009a Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology, Biomarkers & Prevention 18 601-610. (doi:10.1158/1055-9965.epi-08-0546)
12. Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X, et al. 2009b Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics 18 4442-4456. (doi:10.1093/hmg/ddp372)
13. Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, et al. 2010a Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Research 70 9742-9754. (doi:10.1158/0008-5472.CAN-10-1907)
14. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, et al. 2010b A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nature Genetics 42 885-892. (doi:10.1038/ng.669)
15. Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, et al. 2011 Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics 20 3304-3321. (doi:10.1093/hmg/ddr226)
16. Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Lee A, Barrowdale D, Healey S, Sinilnikova OM, et al. 2012 Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Research 14 R33. (doi:10.1186/bcr3121)
17. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA & Abecasis GR 2015 A global reference for human genetic variation. Nature 526 68-74. (doi:10.1038/nature15393)
18. Barnard ME, Boeke CE & Tamimi RM 2015 Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochimica et Biophysica Acta 1856 73-85. (doi:10.1016/j.bbcan.2015.06.002)
19. Barnes DR, Lee A, Easton DF & Antoniou AC 2012 Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. Genetic Epidemiology 36 274-291. (doi:10.1002/gepi.21620)
20. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, et al. 2008 Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299 194-201.
21. Bernholtz S, Laitman Y, Kaufman B, Paluch SS & Friedman E 2011 Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation. Breast Cancer Research and Treatment 129 557-563. (doi:10.1007/s10549-011-1509-z)
22. Bertrand KA, Tamimi RM, Scott CG, Jensen MR, Pankratz V, Visscher D, Norman A, Couch F, Shepherd J, Fan B, et al. 2013 Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Research 15 R104. (doi:10.1186/bcr3570)
23. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, et al. 2013 Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics 45 371-384, 384e371-372. (doi:10.1038/ng.2566)
24. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, et al. 2010 Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics 42 880-884. (doi:10.1038/ng.666)
25. Breast Cancer Association Consortium 2006 Commonly studied singlenucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. Journal of National Cancer Institute 98 1382-1396. (doi:10.1093/jnci/djj374)
26. Breast Cancer Family Registry 2008 Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years. Breast Cancer Research and Treatment 109 67-75. (doi:10.1007/s10549-007-9621-9)
27. Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, Peock S, Eeles RA, Cook M, Chu C, et al. 2007 Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. Journal of Clinical Oncology 25 3831-3836. (doi:10.1200/JCO.2007.11.1179)
28. Brohet RM, Velthuizen ME, Hogervorst FB, Ej Meijers-Heijboer H, Seynaeve C, Collee MJ, Verhoef S, Ausems MG, Hoogerbrugge N, van Asperen CJ, et al. 2014 Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. Journal of Medical Genetics 51 98-107. (doi:10.1136/jmedgenet-2013-101974)
29. Brunet JS, Ghadirian P, Rebbeck TR, Lerman C, Garber JE, Tonin PN, Abrahamson J, Foulkes WD, Daly M, Wagner-Costalas J, et al. 1998 Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. Journal of National Cancer Institute 90 761-766. (doi:10.1093/jnci/90.10.761)
30. Cai Q, Long J, Lu W, Qu S, Wen W, Kang D, Lee JY, Chen K, Shen H, Shen CY, et al. 2011 Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. Human Molecular Genetics 20 4991-4999. (doi:10.1093/hmg/ddr405)
31. Cai Q, Zhang B, Sung H, Low SK, Kweon SS, Lu W, Shi J, Long J, Wen W, Choi JY, et al. 2014 Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nature Genetics 46 886-890. (doi:10.1038/ng.3041)
32. Campa D, Kaaks R, Le Marchand L, Haiman CA, Travis RC, Berg CD, Buring JE, Chanock SJ, Diver WR, Dostal L, et al. 2011 Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. Journal of National Cancer Institute 103 1252-1263. (doi:10.1093/jnci/djr265)
33. Chai X, Domchek S, Kauff N, Rebbeck T & Chen J 2015 RE: breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. Journal of National Cancer Institute 107. (doi:10.1093/jnci/djv033)
34. Chang-Claude J, Andrieu N, Rookus M, Brohet R, Antoniou AC, Peock S, Davidson R, Izatt L, Cole T, Nogues C, et al. 2007 Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology, Biomarkers & Prevention 16 740-746. (doi:10.1158/1055-9965.epi-06-0829)
35. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, et al. 2006 Characterization of BRCA1 and BRCA2 mutations in a large United States sample. Journal of Clinical Oncology 24 863-871. (doi:10.1200/JCO.2005.03.6772)
36. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE & Cimba 2007 An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: The Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Research 9 104. (doi:10.1186/bcr1670)
37. Clark AS & Domchek SM 2011 Clinical management of hereditary breast cancer syndromes. Journal of Mammary Gland Biology and Neoplasia 16 17-25. (doi:10.1007/s10911-011-9200-x)
38. Colilla S, Kantoff PW, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Brown M, Weber BL, et al. 2006 The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis 27 599-605. (doi:10.1093/carcin/bgi246)
39. Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, Wang X, Kirchhoff T, et al. 2012 Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers & Prevention 21 645-657. (doi:10.1158/1055-9965.epi-11-0888)
40. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, et al. 2013 Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genetics 9 e1003212. (doi:10.1371/journal.pgen.1003212)
41. Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H, et al. 2016 Identification of four novel susceptibility loci for estrogen receptor negative breast cancer. Nature Communications 7 11375. (doi:10.1038/ncomms11375)
42. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S, et al. 2007 A common coding variant in CASP8 is associated with breast cancer risk. Nature Genetics 39 352-358. (doi:10.1038/ng1981)
43. Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, Weber B, Moller P, Offit K, Kim-Sing C, et al. 2005 Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. International Journal of Cancer 117 988-991. (doi:10.1002/ijc.21273)
44. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, et al. 2006 Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Lancet Oncology 7 223-229. (doi:10.1016/S1470-2045(06)70585-X)
45. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, et al. 2010 Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304 967-975. (doi:10.1001/jama.2010.1237)
46. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, et al. 2016 Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics 48 374-386. (doi:10.1038/ng.3521)
47. Easton DF, Ford D & Bishop DT 1995 Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. American Journal of Human Genetics 56 265-271.
48. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, et al. 2007 Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447 1087-1093. (doi:10.1038/nature05887)
49. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, et al. 2005 Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. Journal of Clinical Oncology 23 7491-7496. (doi:10.1200/JCO.2004.00.7138)
50. Evans DG, Harkness E, Lalloo F & Howell A 2014 Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies. Journal of Medical Genetics 51 573-580. (doi:10.1136/jmedgenet-2014-102336)
51. Falconer H, Yin L, Gronberg H & Altman D 2015 Ovarian cancer risk after salpingectomy: A nationwide population-based study. Journal of National Cancer Institute 107. (doi:10.1093/jnci/dju410)
52. Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, Walker K, Zelenika D, Gut I, Heath S, Palles C, et al. 2011 Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. Journal of National Cancer Institute 103 425-435. (doi:10.1093/jnci/djq563)
53. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, et al. 1998 Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. American Journal of Human Genetics 62 676-689. (doi:10.1086/301749)
54. French JD, Ghoussaini M, Edwards SL, Meyer KB, Michailidou K, Ahmed S, Khan S, Maranian MJ, O'Reilly M, Hillman KM, et al. 2013 Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. American Journal of Human Genetics 92 489-503. (doi:10.1016/j.ajhg.2013.01.002)
55. Friebel TM, Domchek SM & Rebbeck TR 2014 Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. Journal of National Cancer Institute 106 dju091. (doi:10.1093/jnci/dju091)
56. Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, et al. 2014 Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. PNAS 111 14205-14210. (doi:10.1073/pnas.1415979111)
57. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, Orr N, Rhie SK, Riboli E, Feigelson HS, et al. 2013 Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nature Genetics 45 392-398, 398e391-392. (doi:10.1038/ng.2561)
58. Garcia-Closas M, Gunsoy NB & Chatterjee N 2014 Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer. Journal of National Cancer Institute 106. (doi:10.1093/jnci/djv127)
59. Gaudet MM, Kuchenbaecker KB, Vijai J, Klein RJ, Kirchhoff T, McGuffog L, Barrowdale D, Dunning AM, Lee A, Dennis J, et al. 2013 Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genetics 9 e1003173. (doi:10.1371/journal.pgen.1003173)
60. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensburg EJ, Dunning AM, et al. 1995 Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genetics 11 428-433. (doi:10.1038/ng1295-428)
61. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR & Easton D 1997 Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nature Genetics 15 103-105. (doi:10.1038/ng0197-103)
62. Ghadirian P, Lubinski J, Lynch H, Neuhausen SL, Weber B, Isaacs C, Baruch RG, Randall S, Ainsworth P, Friedman E, et al. 2004 Smoking and the risk of breast cancer among carriers of BRCA mutations. International Journal of Cancer 110 413-416. (doi:10.1002/ijc.20106)
63. Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks E, Dennis J, Wang Q, Humphreys MK, Luccarini C, et al. 2012 Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics 44 312-318. (doi:10.1038/ng.1049)
64. Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, Domchek S, Isaacs C, et al. 2009 Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. Breast Cancer Research and Treatment 114 127-135. (doi:10.1007/s10549-008-9977-5)
65. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, et al. 2010 A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics 42 874-879. (doi:10.1038/ng.668)
66. Gronwald J, Byrski T, Huzarski T, Cybulski C, Sun P, Tulman A, Narod SA & Lubinski J 2006a Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Research and Treatment 95 105-109. (doi:10.1007/s10549-005-9051-5)
67. Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, et al. 2006b Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. International Journal of Cancer 118 2281-2284. (doi:10.1002/ijc.21536)
68. Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, et al. 2006 BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiology Biomarkers & Prevention 15 1863-1870. (doi:10.1158/1055-9965.epi-06-0258)
69. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, et al. 2011 A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nature Genetics 43 1210-1214. (doi:10.1038/ng.985)
70. Hartmann LC & Lindor NM 2016 The role of risk-reducing surgery in hereditary breast and ovarian cancer. New England Journal of Medicine 374 454-468. (doi:10.1056/NEJMra1503523)
71. Heemskerk-Gerritsen BA, Hooning MJ & Rookus MA 2015a Response. Journal of National Cancer Institute 107.
72. Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collee JM, van Doorn HC, Gomez Garcia EB, Kets CM, van Leeuwen FE, Meijers-Heijboer HE, et al. 2015b Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. Journal of National Cancer Institute 107. (doi:10.1093/jnci/djv033)
73. Hein R, Maranian M, Hopper JL, Kapuscinski MK, Southey MC, Park DJ, Schmidt MK, Broeks A, Hogervorst FB, Bueno-de-Mesquita HB, et al. 2012 Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE 7 e42380. (doi:10.1371/journal.pone.0042380)
74. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, Easton DF & Venter DJ 1999 Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiology Biomarkers & Prevention 8 741-747.
75. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, et al. 2007 A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nature Genetics 39 870-874. (doi:10.1038/ng2075)
76. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, et al. 1999 Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354 1846-1850. (doi:10.1016/S0140-6736(99)04336-6)
77. Jernstrom H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, et al. 2004 Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of National Cancer Institute 96 1094-1098. (doi:10.1093/jnci/djh211)
78. Jervis S, Song H, Lee A, Dicks E, Tyrer J, Harrington P, Easton DF, Jacobs IJ, Pharoah PP & Antoniou AC 2014 Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. Journal of Medical Genetics 51 108-113. (doi:10.1136/jmedgenet-2013-102015)
79. Karlan BY, Berchuck A & Mutch D 2007 The role of genetic testing for cancer susceptibility in gynecologic practice. Obstetrics & Gynecology 110 155-167. (doi:10.1097/01.aog.0000269050.79143.84)
80. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, et al. 2008 Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. Journal of Clinical Oncology 26 1331-1337. (doi:10.1200/JCO.2007.13.9626)
81. Kelsey JL, Gammon MD & John EM 1993 Reproductive factors and breast cancer. Epidemiology Review 15 36-47.
82. Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C, Weber B, Kim-Sing C, Foulkes WD, Gershoni-Baruch R, et al. 2005 Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control 16 667-674. (doi:10.1007/s10552-005-1724-1)
83. Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, Foulkes WD, Ghadirian P, Tung N, Ainsworth P, et al. 2012a Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiology Biomarkers & Prevention 21 1089-1096. (doi:10.1158/1055-9965.epi-12-0201)
84. Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, Foulkes WD, Ghadirian P, Neuhausen SL, Demsky R, Tung N, et al. 2012b Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research 14 R42. (doi:10.1186/bcr3138)
85. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP & Greene MH 2005 Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. Journal of Clinical Oncology 23 8629-8635. (doi:10.1200/JCO.2005.02.9199)
86. Kuchenbaecker K, Neuhausen S, Robson M, Barrowdale D, McGuffog L, Mulligan A, Andrulis I, Spurdle A, Schmidt M, Schmutzler R, et al. 2014 Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research 16 3416. (doi:10.1186/s13058-014-0492-9)
87. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, et al. 2015 Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics 47 164-171. (doi:10.1038/ng.3185)
88. Kwong A, Shin VY, Ho JC, Kang E, Nakamura S, Teo SH, Lee AS, Sng JH, Ginsburg OM, Kurian AW, et al. 2016 Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. Journal of Medical Genetics 53 15-23. (doi:10.1136/jmedgenet-2015-103132)
89. Lawrenson K, Kar S, McCue K, Kuchenbaecker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, et al. 2016 Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications [in press].
90. Lecarpentier J, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Caron O, Fricker JP, Gladieff L, Faivre L, Sobol H, et al. 2011 Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO). Breast Cancer Research and Treatment 130 927-938. (doi:10.1007/s10549-011-1655-3)
91. Lecarpentier J, Nogues C, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Fricker JP, Caron O, Stoppa-Lyonnet D, Berthet P, Faivre L, et al. 2012 Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO). Breast Cancer Research 14 R99. (doi:10.1186/bcr3218)
92. Long J, Cai Q, Sung H, Shi J, Zhang B, Choi JY, Wen W, Delahanty RJ, Lu W, Gao YT, et al. 2012 Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. PLoS Genetics 8 e1002532. (doi:10.1371/journal.pgen.1002532)
93. Mavaddat N, Pharoah PD, Blows F, Driver KE, Provenzano E, Thompson D, Macinnis RJ, Shah M, Team S, Easton DF, et al. 2010 Familial relative risks for breast cancer by pathological subtype: A population-based cohort study. Breast Cancer Research 12 R10. (doi:10.1186/bcr2476)
94. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, et al. 2012 Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers & Prevention 21 134-147. (doi:10.1158/1055-9965.epi-11-0775)
95. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, et al. 2013 Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Journal of National Cancer Institute 105 812-822. (doi:10.1093/jnci/djt095)
96. Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, Wang Q, Dennis J, Dunning AM, Shah M, et al. 2015 Prediction of breast cancer risk based on profiling with common genetic variants. Journal of National Cancer Institute 107.
97. McCormack VA & dos Santos Silva I 2006 Breast density and parenchymal patterns as markers of breast cancer risk: A metaanalysis. Cancer Epidemiology Biomarkers & Prevention 15 1159-1169. (doi:10.1158/1055-9965.epi-06-0034)
98. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, et al. 2007 Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study. Lancet Oncology 8 26-34. (doi:10.1016/S1470-2045(06)70983-4)
99. Meyer KB, O'Reilly M, Michailidou K, Carlebur S, Edwards SL, French JD, Prathalingham R, Dennis J, Bolla MK, Wang Q, et al. 2013 Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. American Journal of Human Genetics 93 1046-1060. (doi:10.1016/j. ajhg.2013.10.026)
100. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, et al. 2013 Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics 45 353-361. (doi:10.1038/ng.2563)
101. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, Maranian MJ, Bolla MK, Wang Q, Shah M, et al. 2015 Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics 47 373-380. (doi:10.1038/ng.3242)
102. Milne RL & Antoniou AC 2011 Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Annals of Oncology 22 i11-i17. (doi:10.1093/annonc/mdq660)
103. Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Diez O, Alonso MC, Lazaro C, Blanco I, et al. 2008 The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clinical Cancer Research 14 2861-2869. (doi:10.1158/1078-0432.CCR-07-4436)
104. Milne RL, Gaudet MM, Spurdle AB, Fasching PA, Couch FJ, Benitez J, Arias Perez JI, Zamora MP, Malats N, Dos Santos Silva I, et al. 2010a Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: A combined case-control study. Breast Cancer Research 12 R110. (doi:10.1186/bcr2797)
105. Milne RL, Osorio A, Cajal T, Baiget M, Lasa A, Diaz-Rubio E, de la Hoya M, Caldes T, Teule A, Lazaro C, et al. 2010b Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment 119 221-232. (doi:10.1007/s10549-009-0394-1)
106. Milne RL, Burwinkel B, Michailidou K, Arias-Perez JI, Zamora MP, Menendez-Rodriguez P, Hardisson D, Mendiola M, Gonzalez-Neira A, Pita G, et al. 2014a Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics 23 6096-6111. (doi:10.1093/hmg/ddu311)
107. Milne RL, Herranz J, Michailidou K, Dennis J, Tyrer JP, Zamora MP, Arias-Perez JI, Gonzalez-Neira A, Pita G, Alonso MR, et al. 2014b A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. Human Molecular Genetics 23 1934-1946. (doi:10.1093/hmg/ddt581)
108. Mitchell G, Antoniou AC, Warren R, Peock S, Brown J, Davies R, Mattison J, Cook M, Warsi I, Evans DG, et al. 2006 Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Research 66 1866-1872. (doi:10.1158/0008-5472.CAN-05-3368)
109. Nakamura S, Kwong A, Kim SW, Iau P, Patmasiriwat P, Dofitas R, Aryandono T, Hu Z, Huang CS, Ginsburg O, et al. 2016 Current status of the management of hereditary breast and ovarian cancer in Asia: first report by the Asian BRCA Consortium. Public Health Genomics 19 53-60. (doi:10.1159/000441714)
110. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los RP, et al. 2000 Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356 1876-1881. (doi:10.1016/S0140-6736(00)03258-X)
111. Narod SA, Sun P & Risch HA 2001 Ovarian cancer, oral contraceptives, and BRCA mutations. New England Journal of Medicine 345 1706-1707. (doi:10.1056/NEJM200112063452312)
112. Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, et al. 2002 Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of National Cancer Institute 94 1773-1779. (doi:10.1093/jnci/94.23.1773)
113. Nickels S, Truong T, Hein R, Stevens K, Buck K, Behrens S, Eilber U, Schmidt M, Haberle L, Vrieling A, et al. 2013 Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genetics 9 e1003284. (doi:10.1371/journal. pgen.1003284)
114. Orr N, Dudbridge F, Dryden N, Maguire S, Novo D, Perrakis E, Johnson N, Ghoussaini M, Hopper JL, Southey MC, et al. 2015 Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics 24 2966-2984. (doi:10.1093/hmg/ddv035)
115. Parker WH, Jacoby V, Shoupe D & Rocca W 2009 Effect of bilateral oophorectomy on women's long-term health. Women's Health 5 565-576. (doi:10.2217/whe.09.42)
116. Passaperuma K, Warner E, Hill KA, Gunasekara A & Yaffe MJ 2010 Is mammographic breast density a breast cancer risk factor in women with BRCA mutations? Journal of Clinical Oncology 28 3779-3783. (doi:10.1200/JCO.2009.27.5933)
117. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, et al. 2013 Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications 4 1627. (doi:10.1038/ncomms2613)
118. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J & Stratton MR 1999 Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. Journal of National Cancer Institute 91 943-949. (doi:10.1093/jnci/91.11.943)
119. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, et al. 2013 GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics 45 362-370, 370e361-362. (doi:10.1038/ng.2564)
120. Phillips KA, Butow PN, Stewart AE, Chang JH, Weideman PC, Price MA, McLachlan SA, Lindeman GJ, McKay MJ, Friedlander ML, et al. 2005 Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. Familial Cancer 4 105-113. (doi:10.1007/s10689-004-6129-x)
121. Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, Frost D, Easton DF, Ellis S, Friedlander ML, et al. 2013 Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology 31 3091-3099. (doi:10.1200/JCO.2012.47.8313)
122. Ramon YCT, Chirivella I, Miranda J, Teule A, Izquierdo A, Balmana J, Sanchez-Heras AB, Llort G, Fisas D, Lope V, et al. 2015 Mammographic density and breast cancer in women from high risk families. Breast Cancer Research 17 93. (doi:10.1186/s13058-015-0604-1)
123. Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ, et al. 2010 Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Journal of National Cancer Institute 103 105-116. (doi:10.1093/jnci/djq494)
124. Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Sinilnikova OM, Healey S, Barrowdale D, et al. 2012 Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Human Mutation 33 690-702. (doi:10.1002/humu.22025)
125. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, et al. 1999 Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. Journal of National Cancer Institute 91 1475-1479. (doi:10.1093/jnci/91.17.1475)
126. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, et al. 2002 Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New England Journal of Medicine 346 1616-1622. (doi:10.1056/NEJMoa012158)
127. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, et al. 2015 Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313 1347-1361. (doi:10.1001/jama.2014.5985)
128. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, et al. 2001 Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. American Journal of Human Genetics 68 700-710. (doi:10.1086/318787)
129. Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr, Roger VL, Melton LJ 3rd & Rocca WA 2009a Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 16 15-23. (doi:10.1097/gme.0b013e31818888f7)
130. Rivera CM, Grossardt BR, Rhodes DJ & Rocca WA 2009b Increased mortality for neurological and mental diseases following early bilateral oophorectomy. Neuroepidemiology 33 32-40. (doi:10.1159/000211951)
131. Rudolph A, Milne RL, Truong T, Knight JA, Seibold P, Flesch-Janys D, Behrens S, Eilber U, Bolla MK, Wang Q, et al. 2015 Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. International Journal of Cancer 136 E685-E696. (doi:10.1002/ijc.29188)
132. Senst N, Llacuachaqui M, Lubinski J, Lynch H, Armel S, Neuhausen S, Ghadirian P, Sun P, Narod SA & Hereditary Breast Cancer Study Group 2013 Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation. Clinical Genetics 84 43-46. (doi:10.1111/cge.12037)
133. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, et al. 2013 Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications 4 1628. (doi:10.1038/ncomms2629)
134. Siddiq A, Couch FJ, Chen GK, Lindstrom S, Eccles D, Millikan RC, Michailidou K, Stram DO, Beckmann L, Rhie SK, et al. 2012 A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics 21 5373-5384. (doi:10.1093/hmg/dds381)
135. Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A, Kedar-Barnes I, Shiri-Sverdlov R, Dagan E, Tsabari S, Shohat M, et al. 2006 Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. PNAS 103 3770-3774. (doi:10.1073/pnas.0511301103)
136. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, Dicioccio R, et al. 2009 A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics 41 996-1000. (doi:10.1038/ng.424)
137. Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, Fridley BL, Tyrer JP, Alsop J, Jimenez-Linan M, et al. 2014 The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Human Molecular Genetics 23 4703-4709. (doi:10.1093/hmg/ddu172)
138. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, et al. 2007 Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nature Genetics 39 865-869. (doi:10.1095/biolreprod.111.093252)
139. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF, Jakobsdottir M, Bergthorsson JT, Gudmundsson J, Aben KK, et al. 2008 Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nature Genetics 40 703-706. (doi:10.1038/ng.131)
140. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson SE, Hutchinson A, Wang Z, Yu K, et al. 2009 A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nature Genetics 41 579-584. (doi:10.1038/ng.353)
141. Thompson D, Easton D & Breast Cancer Linkage Consortium 2001 Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. American Journal of Human Genetics 68 410-419. (doi:10.1086/318181)
142. Thompson D, Easton D & Breast Cancer Linkage Consortium 2002 Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiology Biomarkers & Prevention 11 329-336. (doi:10.1210/en.2002-220652)
143. Travis RC, Reeves GK, Green J, Bull D, Tipper SJ, Baker K, Beral V, Peto R, Bell J, Zelenika D, et al. 2010 Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet 375 2143-2151. (doi:10.1016/S0140-6736(10)60636-8)
144. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, et al. 2010 Genome-wide association study identifies five new breast cancer susceptibility loci. Nature Genetics 42 504-507. (doi:10.1038/ng.586)
145. Whittemore AS 2007 Assessing environmental modifiers of disease risk associated with rare mutations. Human Heredity 63 134-143. (doi:10.1159/000099185)
146. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, et al. 2011 Associations of breast cancer risk factors with tumor subtypes: A pooled analysis from the Breast Cancer Association Consortium studies. Journal of National Cancer Institute 103 250-263. (doi:10.1093/jnci/djq526)
147. Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, Wen W, Levy S, Deming SL, Haines JL, et al. 2009 Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nature Genetics 41 324-328. (doi:10.1038/ng.318)